Amryt Pharma plc, formerly Fastnet Equity plc, is a United Kingdom-based specialty pharmaceutical company. The Company focuses on developing and delivering treatments for patients with rare and orphan diseases. The Company's products include Episalvan and Imlan. The Company's products focus on developing somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases, including acromegaly and Cushing's disease. The Company's Episalvan is a prescription pharmaceutical product, which accelerates wound healing. The Company's Episalvan consists of two ingredients, such as betulin-based active ingredient and sunflower oil as the excipient. The Company's Imlan products have regenerative and anti-inflammatory properties. Betulin is the active ingredient in the Imlan products and functions as the stabilizer of the creams and lotions. The Company's Imlan Creme Pur consists of Betulin, oil and water ingredients.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: LON:FAST
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: GBX 2.91
- 200 Day Moving Avg: GBX 2.54
- 52 Week Range: GBX 1.85 - GBX 3.90
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Average Volume: 939,809 shs.
Frequently Asked Questions for Amryt Pharma PLC (LON:FAST)
What is Amryt Pharma PLC's stock symbol?
Amryt Pharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "FAST."
Where is Amryt Pharma PLC's stock going? Where will Amryt Pharma PLC's stock price be in 2017?
2 brokerages have issued twelve-month price targets for Amryt Pharma PLC's shares. Their forecasts range from GBX 60 to GBX 62. On average, they expect Amryt Pharma PLC's stock price to reach GBX 61 in the next year. View Analyst Ratings for Amryt Pharma PLC.
Who are some of Amryt Pharma PLC's key competitors?
Some companies that are related to Amryt Pharma PLC include Partnership Assurance Group PLC (PA), Royal Dutch Shell Plc (RDSB), HSBC Holdings plc (HSBA), Unilever plc (ULVR), British American Tobacco plc (BATS), BP plc (BP), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Vodafone Group plc (VOD), BHP Billiton plc (BLT), Diageo plc (DGE), Rio Tinto plc (RIO), Lloyds Banking Group PLC (LLOY), Reckitt Benckiser Group Plc (RB), Barclays PLC (BARC), Prudential plc (PRU), Shire PLC (SHP) and Glencore PLC (GLEN).
Who are Amryt Pharma PLC's key executives?
Amryt Pharma PLC's management team includes the folowing people:
- Joe Wiley, Chief Executive Officer, Executive Director
- , Rory Nealon, Chief Financial Officer, Chief Operating Officer, Executive Director, Company Secretary, Harry Thomas Stratford, Independent Non-Executive Chairman of the Board, James Culverwell, Senior Non-Executive Independent Director, Ray Stafford, Non-Executive Independent Director, Markus Ziener, Non-Executive Independent Director,
How do I buy Amryt Pharma PLC stock?
Shares of Amryt Pharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Amryt Pharma PLC's stock price today?
MarketBeat Community Rating for Amryt Pharma PLC (LON FAST)MarketBeat's community ratings are surveys of what our community members think about Amryt Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Amryt Pharma PLC stock can currently be purchased for approximately GBX 2.97.
Consensus Ratings for Amryt Pharma PLC (LON:FAST) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Hold Rating, 1 Buy Rating|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||GBX 61|
Analysts' Ratings History for Amryt Pharma PLC (LON:FAST)
(Data available from 5/29/2015 forward)
|5/29/2017||Beaufort Securities||Reiterated Rating||Speculative Buy||GBX 62|
|4/24/2017||Stifel Nicolaus||Reiterated Rating||Buy||GBX 60|
Earnings History for Amryt Pharma PLC (LON:FAST)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Amryt Pharma PLC (LON:FAST)
Current Year EPS Consensus Estimate: $-0.33 EPS
Dividend History for Amryt Pharma PLC (LON:FAST)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Amryt Pharma PLC (LON:FAST)Insider Trades by Quarter for Amryt Pharma PLC (LON:FAST)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
Headline Trends for Amryt Pharma PLC (LON:FAST)
Latest Headlines for Amryt Pharma PLC (LON:FAST)
Amryt Pharma PLC (FAST) Chart for Monday, May, 29, 2017